OMFRELA (registration number 4843523) is a United States trademark of DAIICHI SANKYO COMPANY, LIMITED. The goods and services are: Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, sclerosis, atherosclerosis, diabetic nephropathy, stroke, heart attack, hypercholesterolemia, dyslipidemia, anemia, blood disorders, diabetes, thyroid function disease, cancer, oncological disease, leukemia, metastasis, autoimmune disease, rheumatoid arthritis, allergy, bacterial infection, viral infection, fungal infection, inflammation, sepsis, spinal cord injury, musculoskeletal disorders, pain, central nervous system disease, neurological disease, mood disorders, osteoporosis, Alzheimer’s disease, obesity, anorexia, urinary and kidney disease, respiratory disease, gastrointestinal disease, constipation; vaccines; diagnostic reagents and contrast media for medical use . The correspondent is Mark Lebow.
This trademark was filed on March 19, 2015 as United States Trademark Application Serial Number 79167962.
Trademark PTO Status
20220703 – NEW REPRESENTATIVE AT IB RECEIVED
20220520 – CANCELLED SECTION 71
20201103 – COURTESY REMINDER – SEC. 71 (6-YR) E-MAILED
20160212 – NOTIFICATION PROCESSED BY IB
20160128 – FINAL DISPOSITION NOTICE SENT TO IB
20160128 – FINAL DISPOSITION PROCESSED
20151203 – GRANT OF PROTECTION CREATED, TO BE SENT TO IB
20151201 – ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Ownership History
DAIICHI SANKYO COMPANY, LIMITED
DAIICHI SANKYO COMPANY, LIMITED
DAIICHI SANKYO COMPANY, LIMITED
File a Trademark
Select IP monitors top trademarks which have been allowed and granted worldwide. We are experts in trademark law. If you are interested in connecting with an IP law attorney or patent law attorney, please contact us via the contact form.